Form 4: Edgewise CSO Sells Shares After Option Exercise

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and subsequently sold 100,000 shares of common stock for approximately $1.46 million.

Summary

• Alan J. Russell, Chief Scientific Officer and Director of Edgewise Therapeutics, Inc. (EWTX), engaged in a series of transactions on August 26, 2025.
• He exercised 100,000 stock options at an exercise price of $0.18 per share.
• Concurrently, he sold 100,000 shares of common stock at an average price of $14.5976 per share.
• The sales were executed in multiple transactions with prices ranging from $14.40 to $14.825 per share.
• Following these transactions, Russell's direct beneficial ownership of common stock decreased from 123,400 shares to 23,400 shares.
• His beneficial ownership of stock options decreased from 1,347,365 to 1,247,365.
• The transactions were conducted under a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can sometimes be viewed negatively, the transaction was pre-planned under a Rule 10b5-1 plan, suggesting a routine liquidity event rather than a signal of negative company prospects. The executive still retains a significant number of options.

Positives

• The exercise of options indicates a significant in-the-money position for the executive, with an exercise price of $0.18 compared to a sale price of $14.5976.
• The sale was conducted under a Rule 10b5-1 plan, suggesting a pre-planned liquidity event rather than an immediate reaction to new information.

Negatives

• An insider sale, particularly by a Chief Scientific Officer, can sometimes be perceived negatively by the market as it reduces the executive's direct equity stake in the company.
• The sale represents a significant portion of the executive's directly held common stock, reducing his direct ownership from 123,400 shares to 23,400 shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reported transactions involve an insider (Chief Scientific Officer and Director) exercising stock options and selling company shares, which is a common type of related party transaction in the context of executive compensation and liquidity.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to short-term price volatility, though the 10b5-1 plan mitigates this.
• Management: The Chief Scientific Officer has realized significant personal gains from long-held options, which is a positive for executive compensation and retention.

Key Dates

Recommendation

The insider sale, while significant in volume, was executed under a pre-arranged 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new, adverse company information. The executive still retains a substantial number of unexercised options. Without additional company-specific news or broader market context, this Form 4 alone does not provide a strong signal for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as investors should await further fundamental updates.

Keywords

Edgewise Therapeutics, EWTX, Insider Trading, Stock Option Exercise, Share Sale, Alan J Russell, Chief Scientific Officer, Director, Form 4, Rule 10b5-1